NCT04182373 is a Phase 3 clinical trial of Antithrombin gamma in Preeclampsia, sponsored by Kyowa Kirin Co., Ltd..

Who is sponsoring NCT04182373?

NCT04182373 is sponsored by Kyowa Kirin Co., Ltd..

What drugs are being tested in NCT04182373?

Interventions in NCT04182373: Antithrombin gamma, physiological saline.

What condition does NCT04182373 study?

NCT04182373 studies Preeclampsia.

Is NCT04182373 still recruiting?

NCT04182373 is currently completed. Last updated 15 November 2023.

Last reviewed 2023-11-15 · How we verify

NCT04182373

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KW-3357 Study in Patients With Early Onset Severe Preeclampsia

Completed Phase 3 Last updated 15 November 2023

What this trial tests

Phase 3 trial testing Antithrombin gamma in Preeclampsia in 181 participants. Completed in 16 June 2023.

Timeline

19 November 2019

Primary endpoint
17 May 2023

16 June 2023

Quick facts

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	181
Start date	19 November 2019
Primary completion	17 May 2023
Estimated completion	16 June 2023
Sites	63 locations across Japan

Drugs / interventions tested

Antithrombin gamma — full drug profile →
physiological saline — full drug profile →

Conditions studied

Preeclampsia — all drugs for Preeclampsia →

Sponsor

Kyowa Kirin Co., Ltd. — full company profile →

Who can join

18 and older, female only, with Preeclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations.
Sakowicz A, Bralewska M, Rybak-Krzyszkowska M, Grzesiak M, et al · · 2023 · cited 28× · PMID 37569476 · DOI 10.3390/ijms241512100
Randomized Study of Antithrombin in Early-Onset Preeclampsia: KOUNO-TORI Study.
Takeda J, Tachibana D, Itakura A, Takagi K, et al · · 2026 · PMID 41789451 · DOI 10.1161/hypertensionaha.125.25431

Verify or expand the search:

Other recruiting trials for Preeclampsia

Currently open trials in the same condition.

NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting

Other Kyowa Kirin Co., Ltd. trials

Trials by the same sponsor.

NCT06926491 — Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） · Phase 3 · recruiting
NCT06812104 — Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06525636 — A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia · Phase 1, PHASE2 · recruiting
NCT06116890 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration · Phase 2 · active not recruiting
NCT06116916 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04182373 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin Co., Ltd.
Last refreshed: 15 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04182373.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing